Loxiglumide|107097-80-3|(CR-1505)-陌孚医药/Medlife

您当前的位置：

Loxiglumide (Synonyms: CR-1505)

目录号: PL05578 纯度: ≥98%

CAS No. :107097-80-3

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Loxiglumide
中文别名	氯谷胺
英文名称	Loxiglumide
英文别名	Pentanoic acid,4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-;CR-1505;Loxiglumide;(+-)-4-((3,4-Dichlorobenzoyl)amino)-5-((3-;(R,S-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylamino)-5-oxo-pentanoic acid);D,L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylamino)-5-oxo-pentanoic acid;D,L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylamino)-5-oxopentanoic asid;Pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxo-, (+-)-;4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-pentanoic acid;CR 1505;4-[(3,4-Dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxopentanoic acid;anoicacid;ntanoicacid;(+-)--5-oxo;LoxigluMide (CR1505);(+-)-4-((3,4-dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxope;d,l-4-(3,4-dichlorobenzoylamino)-5-(n-3-methoxypropylpentylamino)-5-oxo-pent;pentanoicacid,4-((3,4-dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino);5-[amyl(3-methoxypropyl)amino]-4-[(3,4-dichlorobenzoyl)amino]-5-keto-valeric acid
Cas No.	107097-80-3
分子式	C₂₁H₃₀N₂O₅Cl₂
分子量	461.38
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	Loxiglumide 是缩胆囊素 (CCK-1) 受体拮抗剂。
生物活性	Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.
性状	Solid
IC50 & Target[1][2]	CCK-1 receptor
体内研究(In Vivo)	The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest). has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Jia D, et al. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats. World J Gastroenterol. 2015 Jul 7;21(25):7742-53.

溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (216.74 mM)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品